The short answer
Laron syndrome is a congenital condition in which growth hormone receptor defects prevent normal IGF-1 production. Laron and Werner reported in Endocrine-Related Cancer in 2023 that patients with the syndrome do not develop cancer, describing it as of major scientific and translational relevance.
Key facts
- Cause
- Growth hormone receptor defect
- Consequence
- Congenital IGF-1 deficiency
- Reported observation
- Patients do not develop cancer
- 2023 paper
- Laron & Werner (PMID 37343154)
- Journal
- Endocr Relat Cancer
- Historical account
- Laron 2021 (PMID 32964395)
- Follow-up work
- Genome-wide profiling of patient cells
What the condition is
Growth hormone is produced normally, but its receptor does not function, so the signal cannot be received. Since the liver produces IGF-1 in response to that signal, the result is high circulating growth hormone alongside very low IGF-1. This unusual combination separates the two arms of the axis in a way no experiment could deliberately arrange.
Why it is a natural experiment
Deliberately removing IGF-1 from humans for decades is not something anyone could do. A congenital condition does it, and the affected individuals can be followed across a lifetime. That is the only route to observing what lifelong absence of a signalling axis produces, and it is why rare genetic conditions carry evidential weight out of proportion to how many people have them.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
The finding
Laron and Werner state the epidemiological observation directly: patients with Laron syndrome, described as the best-characterised condition among the congenital IGF-1 deficiencies, do not develop cancer. They describe this evasion as emphasising the central role of the growth hormone and IGF-1 system in cancer biology.
Why the mechanism is plausible rather than surprising
IGF-1 is a growth factor. Its signalling promotes cell proliferation and opposes programmed cell death, both processes cancer depends on. A lifelong reduction in that signalling would be expected to reduce the probability of a cell accumulating the changes required to become malignant, and the observation matches the prediction.
What the authors did next
Genome-wide profiling of cells from Laron syndrome patients against normal controls, using immortalised lymphoblastoid lines, to identify differentially expressed genes that might provide a biological foundation for the protection. That moves the work from an epidemiological observation toward a mechanism, which is the necessary next step.
The limits of a rare-condition observation
Laron syndrome cohorts are small, and absence of an event in a small group is weaker evidence than its presence would be. The affected individuals also differ from the general population in more ways than IGF-1 alone. The finding is striking and it is an observation in a rare population, not a controlled comparison.
Frequently asked questions
What causes Laron syndrome?
A growth hormone receptor defect. Growth hormone is produced but cannot be received, so the liver does not produce IGF-1 normally.
What did Laron and Werner report?
That patients with the syndrome do not develop cancer, which they describe as emphasising the central role of the GH-IGF-1 system in cancer biology.
How strong is that evidence?
Striking but limited: cohorts are small, absence of an event is weaker than its presence, and affected individuals differ in more ways than IGF-1 alone.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedLaron Z, Werner H, Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome. Endocr Relat Cancer 2023 (PMID 37343154)pubmed.ncbi.nlm.nih.gov
- PubMedLaron Z, Laron syndrome: a historical perspective. Rev Endocr Metab Disord 2021 (PMID 32964395)pubmed.ncbi.nlm.nih.gov
- PubMedBaxter RC, Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994 (PMID 7532612)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- A Strong Rationale That Did Not TranslateThe IGF-1 receptor was pursued as an oncology target on excellent biological grounds. The clinical programmes largely failed, and why is instructive.
- A Regulatory System, Deliberately EvadedIGF binding proteins restrain IGF-1 availability. LR3 exists to escape them. Set against the Laron findings, that is worth stating plainly.
- Two Hormones, One Feedback LoopGrowth hormone acts on the liver, the liver produces IGF-1, and IGF-1 feeds back to suppress growth hormone. Laron syndrome breaks the loop mid-way.
- Two Receptors Close Enough to Form HybridsThe IGF-1 and insulin receptors share structure and can assemble into hybrids containing subunits of both. Selectivity is therefore never absolute.
- Eighty-Three Residues, and What That ChangesRegulators treat 40 amino acids as the boundary between peptide and protein. At 83 residues, IGF-1 LR3 is well past it - with consequences.